Vaccine and method for treatment of motor neurone diseases

Details for Australian Patent Application No. 2002353486 (hide)

Owner Yeda Research and Development Co. Ltd

Inventors Yoles, Esther; Eisenbach-Schwartz-, Michal

Agent FB Rice

Pub. Number AU-B-2002353486

PCT Number PCT/IL02/00979

PCT Pub. Number WO2003/047500

Priority 60/336,139 06.12.01 US

Filing date 5 December 2002

Wipo publication date 17 June 2003

Acceptance publication date 15 January 2009

International Classifications

A61K 38/16 (2006.01) Medicinal preparations containing peptides - Peptides having more than 20 amino acids

A61K 31/426 (2006.01) - 1,3-Thiazoles

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

A61K 39/39 (2006.01) Medicinal preparations containing antigens or antibodies - characterised by the immunostimulating additives, e.g. chemical adjuvants

A61P 21/00 (2006.01) Drugs for disorders of the muscular or neuromuscular system

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

A61P 27/06 (2006.01) Drugs for disorders of the senses

Event Publications

20 March 2003 Complete Application Filed

  Priority application(s): 60/336,139 06.12.01 US

21 August 2003 Application Open to Public Inspection

  Published as AU-B-2002353486

15 January 2009 Application Accepted

  Published as AU-B-2002353486

14 May 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002353487-HERBAL OPHTHALMIC FORMULATION FOR PREVENTING CATARACT

2002353485-Amphiphilic compounds and vesicles/ liposomes for organ-specific drug targeting